Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Skye To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Skye between November 4, 2024 and October 3, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Dec. 20, 2025 (GLOBE NEWSWIRE) -- Faruqi & Far ...

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025, both dates inclusive (the “Class Period”), of the important January 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Skye securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Skye securities during the class period because the Company allegedly misled investors regarding the viability of its lead drug candidate. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What are the allegations? According to the complaint, during the class peri ...

NEW YORK, Dec. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslr ...

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/p ...

PHILADELPHIA, Dec. 18, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Skye Bioscience, Inc. (NASDAQ: SKYE) ("Skye" or the "Company") on behalf of investors who purchased or otherwise acquired Skye securities during the period of November 4, 2024 through October 3, 2025 (the "Class Period"), inclusive. Investor Deadline: Investors who purchased Skye securities during the Class Period may, no later than January 16, 2026, seek ...

集体诉讼通知 - Gross Law Firm向Skye Bioscience Inc (NASDAQ: SKYE)的股东发布集体诉讼通知 鼓励在特定集体诉讼期内购买股票的股东联系该律所 以探讨可能的首席原告任命事宜 [1] 诉讼核心指控 - 诉讼指控公司在集体诉讼期内 即2024年11月4日至2025年10月3日 发布了重大虚假和/或误导性陈述 和/或未能披露重要信息 [3] - 具体指控包括 公司的主要候选产品nimacimab的效果不如管理层向投资者所宣称的那样有效 [3] - 因此 nimacimab的临床、监管和商业前景被夸大 [3] - 结果导致 被告的公开陈述在所有相关时间点都存在重大虚假和误导性 [3] 诉讼程序相关 - 股东参与集体诉讼的截止日期为2026年1月16日 [4] - 股东注册后将被纳入案件组合监控软件 以便在整个案件生命周期内获取状态更新 [4] - 寻求成为首席原告的截止日期也是2026年1月16日 [4]

诉讼概述 - Levi & Korsinsky律师事务所通知Skye Bioscience Inc (NASDAQ: SKYE)的投资者一项集体诉讼证券诉讼 [1] - 诉讼旨在为在2024年11月4日至2025年10月3日期间因涉嫌证券欺诈而遭受不利影响的投资者挽回损失 [1] - 投资者需在2026年1月16日前请求法院指定其为首席原告 [3] 指控内容 - 起诉书指控被告作出虚假陈述和/或隐瞒事实 [2] - 指控称公司的主要候选产品nimacimab的效果不如被告向投资者引导的那样有效 [2] - 因此nimacimab的临床、监管和商业前景被夸大 [2] - 结果导致被告的公开陈述在所有相关时间都存在重大虚假和误导性 [2] 投资者参与信息 - 在相关时间段内遭受损失的投资者有资格参与 [3] - 参与集体诉讼的成员可能有权获得补偿且无需支付任何自付费用 [3] - 投资者可通过提供的链接、电子邮件或电话联系律师事务所获取更多信息并加入诉讼 [1][3] 律师事务所背景 - Levi & Korsinsky律师事务所在过去20年间为受损股东追回了数亿美元 [4] - 该事务所在处理高风险的复杂证券诉讼方面拥有丰富专业知识 [4] - 公司拥有超过70名员工的团队为客户服务 [4] - 连续七年被ISS证券集体诉讼服务评为美国顶级证券诉讼公司之一 [4]

事件概述 - 律师事务所Levi & Korsinsky, LLP通知Skye Bioscience, Inc投资者一项集体诉讼 该诉讼旨在为在2024年11月4日至2025年10月3日期间因涉嫌证券欺诈而遭受损失的投资者挽回损失 [1] 诉讼核心指控 - 指控公司对主要候选产品nimacimab的疗效做出虚假陈述和/或隐瞒 其实际效果低于公司向投资者传达的水平 [2] - 指控公司因此夸大了nimacimab的临床、监管和商业前景 [2] - 指控公司的公开陈述在所有相关时间均存在重大虚假和误导性 [2] 诉讼程序信息 - 在相关期间遭受损失的投资者 需在2026年1月16日前请求法院任命其为首席原告 [3] - 参与集体诉讼的成员可能有权获得赔偿 且无需支付任何自付费用 [3] 律师事务所背景 - Levi & Korsinsky律师事务所在过去20年间 已为受损股东追回数亿美元（hundreds of millions of dollars） [4] - 该律所在美国ISS证券集体诉讼服务Top 50报告中 连续七年被评为顶级证券诉讼律所之一 [4] - 该律所拥有超过70名员工 在复杂证券诉讼中代表投资者方面拥有广泛专业知识 [4]

核心诉讼事件 - 股东诉讼律师事务所Kuehn Law正在调查Skye Bioscience公司某些高管和董事是否违反了对股东的受托责任 [1] - 根据联邦证券诉讼指控 Skye Bioscience内部人士导致公司对nimacimab的疗效做出不实陈述或未能披露相关信息 [2] - 指控的具体内容包括 nimacimab的实际疗效低于公司宣称的水平 其临床、监管和商业前景被夸大 导致公司公开声明在相关时间段存在重大虚假和误导性 [2] 涉事产品与指控 - 涉事核心产品为nimacimab 公司被指控夸大了该产品的有效性 [2] - 指控指出 由于产品实际疗效不及宣称 导致其临床开发前景、监管审批前景和商业前景均被夸大 [2] - 上述不实陈述和遗漏 致使公司在相关时期的所有公开声明均存在重大虚假和误导性 [2] 股东行动与联系 - 律师事务所呼吁在2024年11月4日之前购买并目前仍持有Skye Bioscience股票的股东与其联系 [3] - 提供的联系渠道为电子邮件justin@kuehn.law或电话(833) 672-0814 联系人为Justin Kuehn律师 [3] - 该律师事务所承担所有案件费用 不向投资者客户收费 并提示股东应立即联系 因为行使权利的时间可能有限 [3]